a 2017

Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic

SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Zbyněk BORTLÍČEK, M. PESEK, V. KOLEK et. al.

Basic information

Original name

Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic

Authors

SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), M. PESEK (203 Czech Republic), V. KOLEK (203 Czech Republic), Karel HEJDUK (203 Czech Republic, belonging to the institution), L. KOUBKOVA (203 Czech Republic), M. ČERNOVSKA (203 Czech Republic), J. KREJCI (203 Czech Republic), M. ZEMANOVA (203 Czech Republic), L. HAVEL (203 Czech Republic), J. ROUBEC (203 Czech Republic), M. HRNCIARIK (203 Czech Republic), F. SALAJKA (203 Czech Republic), H. COUPKOVA (203 Czech Republic), Monika ŠATÁNKOVÁ (203 Czech Republic, belonging to the institution), Andrea BENEJOVÁ (703 Slovakia, belonging to the institution), I. GRYGARKOVA (203 Czech Republic) and P. OPALKA (203 Czech Republic)

Edition

2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30203 Respiratory systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/17:00098275

Organization unit

Faculty of Medicine

Keywords in English

Tyrosine Kinase Inhibitors

Tags

Změněno: 17/5/2018 17:04, Soňa Böhmová

Abstract

V originále

Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic.